[1]冯超凡,胡继红,张学贤,等.DEB-TACE联合MWA及阿帕替尼治疗巨块型肝癌的临床疗效 [J].介入放射学杂志,2022,31(03):254-258.
　FENG Chaofan,HU Jihong,ZHANG Xuexian,et al.DEB-TACE combined with MWA and apatinib for the treatment of huge hepatocellular carcinoma[J].journal interventional radiology,2022,31(03):254-258.
点击复制

DEB-TACE联合MWA及阿帕替尼治疗巨块型肝癌的临床疗效
()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
31
期数:
2022年03
页码:
254-258
栏目:
肿瘤介入
出版日期:
2022-03-25

文章信息/Info

Title:
DEB-TACE combined with MWA and apatinib for the treatment of huge hepatocellular carcinoma
作者:
冯超凡;  胡继红;  张学贤;  游占亮;  王 飞;  赵 卫;  万 程;  熊 峰
Author(s):
FENG Chaofan;  HU Jihong;  ZHANG Xuexian;  YOU Zhanliang;  WANG Fei;  ZHAO Wei;  WAN Cheng;  XIONG Feng.
Department of Medical Imaging， First Affiliated Hospital of Kunming Medical University， Kunming， Yunnan Province 650032， China
关键词:
【关键词】 巨块型肝癌;  载药微球;  微波消融;  阿帕替尼
文献标志码:
A
摘要:
【摘要】 目的 探讨DEB-TACE联合MWA及阿帕替尼治疗巨块型肝癌的临床疗效。方法 回顾性分析昆明医科大学第一附属医院2017年7月至2019年7月采用载药微球（DEB）-TACE联合MWA及阿帕替尼治疗的23例巨块型肝癌患者的临床资料，根据改良实体肿瘤评价标准评估临床疗效，评估DEB-TACE及消融术后并发症及口服阿帕替尼的不良反应，分析影响患者预后的因素。结果 患者接受治疗后6、12个月，总生存率（OS）分别为91.3%、78.3%；在1、3、6、12个月，患者客观缓解率（ORR）分别为56.5%、87.0%、78.2%、87.0%，其中位无进展生存期（mPFS）为14.0个月， mOS为27.0个月。DEB-TACE术后不良反应主要为腹痛、恶心、呕吐、发热及肝功能损伤等，消融术后并发症主要为气胸、肝包膜下出血、疼痛等，阿帕替尼不良反应主要为手足综合征、继发性高血压、蛋白尿、脱发及皮肤色素沉着症等。所有并发症均通过支持治疗得到缓解，所有不良反应均未超过3级，且通过支持治疗或调整药量得到控制。结论 DEB-TACE联合MWA及阿帕替尼对巨块型中晚期肝癌具有明显疗效。

参考文献/References:

［1］ Torre LA， Bray F， Siegel RL， et al. Global cancer statistics， 2012［J］. CA Cancer J Clin， 2015， 65： 87- 108.
［2］ Lau WY， Lai ECH. Loco- regional intervention for hepatocellular carcinoma［J］. J Intervent Med， 2019， 2： 43- 46.
［3］ Yu JI， Park HC. Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis［J］. World J Gastro- enterol， 2016， 22： 6851- 6863.
［4］ Lencioni R. New data supporting modified RECIST（mRECIST） for hepatocellular carcinoma［J］. Clin Cancer Res， 2013， 19： 1312- 1314.
［5］ Freites- Martinez A， Santana N， Arias- Santiago S， et al. Using the common terminology criteria for adverse events（CTCAE- version 5.0） to evaluate the severity of adverse events of anticancer therapies［J］. Actas Dermosifiliogr， 2021， 112： 90- 92.
［6］ Zhao S， Zhang T， Dou W， et al. A comparison of transcatheter arterial chemoembolization used with and without apatinib for intermediate- to advanced- stage hepatocellular carcinoma： a systematic review and meta- analysis［J］. Ann Transl Med， 2020， 8： 542.
［7］ Lin G， Wang B， Wu X， et al. Efficacy and safety of apatinib treatment for patients with advanced intrahepatic cholangiocar- cinoma［J］. Cancer Manag Res， 2020， 12： 11523- 11526.
［8］ Wu Y， Qi H， Cao F， et al. TACE- sorafenib with thermal ablation has survival benefits in patients with huge unresectable hepatocellular carcinoma［J］. Front Pharmacol， 2020， 11：1130.
［9］ Hernandez JI， Cepeda MF， Valdes F， et al. Microwave ablation： state- of- the- art review［J］. Onco Targets Ther， 2015， 8： 1627- 1632.
［10］ Shuanggang C， Shen L， Qiu Z， et al. Transarterial chemoembo- lization combined with microwave ablation and apatinib in patients with Barcelona clinic liver cancer stage C hepatocellular carcinoma： a propensity score matching analysis［J］. J Cancer Res Ther， 2020， 16： 250- 257.
［11］ Golfieri R， Giampalma E， Renzulli M， et al. Randomised controlled trial of doxorubicin- eluting beads vs conventional chemoembolisation for hepatocellular carcinoma［J］. Br J Cancer， 2014， 111： 255- 264.
［12］ Xie ZB， Wang XB， Peng YC， et al. Systematic review comparing the safety and efficacy of conventional and drug- eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma［J］. Hepatol Res， 2015， 45： 190- 200.
［13］ Kobayashi S， Tajiri K， Murayama A， et al. Drug- eluting bead- transcatheter arterial chemoembolization for advanced hepato-cellular carcinoma refractory to conventional lipiodol- based transcatheter arterial chemoembolization［J］. J Hepatocell Carci-noma， 2020， 7： 181- 189.
［14］ Zhang L， Zhong BY，Hu Bo. Stratification of portal vein- invaded hepatocellular carcinoma treated with transarterial chemoem-bolization monotherapy［J］. J Intervent Med， 2020， 3： 201- 207.
［15］ 陆 阳，汤蕊嘉，谢璇丞，等． TACE联合阿帕替尼治疗中晚期肝细胞癌无进展生存时间的影响因素分析［J］． 介入放射学杂志， 2020， 29：246- 250．

相似文献/References:

[1]吴志远,丁晓毅,黄 蔚,等.门脉粒子支架联合载药微球栓塞治疗肝癌7例[J].介入放射学杂志,2017,(02):161.
　WU Zhiyuan,DING Xiaoyi,HUANG Wei,et al.Portal 125I seed stent implantation combined with drug-loaded microsphere embolization for the treatment of HCC： initial results in 7 patients[J].journal interventional radiology,2017,(03):161.
[2]赵 倩,颜志平.载药微球经导管动脉化疗栓塞治疗肝癌研究进展 [J].介入放射学杂志,2017,(11):1052.
　ZHAO Qian,YAN Zhiping.Transarterial chemoembolization with drug- eluting beads for the treatment of hepatocellular carcinoma： recent progress in research[J].journal interventional radiology,2017,(03):1052.
[3]李 鑫,李 臻,李 刚,等.载药微球化疗栓塞治疗下肢梭形细胞肉瘤1例[J].介入放射学杂志,2018,27(02):111.
　LI Xin,LI Zhen,LI Gang,et al.Successful treatment of lower limb spindle cell sarcoma by using chemoembolization with drug- eluting beads： report of one case[J].journal interventional radiology,2018,27(03):111.
[4]于 奇,吴 杰,高 飞,等.载药微球加载贝伐珠单抗治疗难治性实体瘤4例[J].介入放射学杂志,2019,28(01):81.
　YU Qi,WU Jie,GAO Fei,et al.HepaSphere loaded with bevacizumab for the treatment of refractory solid tumors： preliminary results in 4 patients[J].journal interventional radiology,2019,28(03):81.
[5]李亚华,段旭华,韩新巍,等.TACE术中应用三氧化二砷CalliSpheres载药栓塞微球治疗BCLC B期原发性肝癌13例 [J].介入放射学杂志,2019,28(03):232.
　LI Yahua,DUAN Xuhua,HAN Xinwei,et al.TACE by using arsenic trioxide drug- bearing CalliSpheres beads for the treatment of BCLC stage B HCC： preliminary results in 13 patients[J].journal interventional radiology,2019,28(03):232.
[6]翟 越,潘文秋,赵 卫,等.CalliSpheres联合阿帕替尼治疗肝癌的安全性和有效性[J].介入放射学杂志,2020,29(05):462.
　ZHAI Yue,PAN Wenqiu,ZHAO Wei,et al.The safety and effectiveness of CalliSpheres combined with apatinib for the treatment of hepatocellular carcinoma[J].journal interventional radiology,2020,29(03):462.
[7]荆 霞,徐 圣.Callispheres栓塞后综合征的综合护理模式与常规护理模式比较[J].介入放射学杂志,2020,29(07):722.
　JING Xia,XU Sheng..Comprehensive nursing mode versus routine nursing mode for post- embolization syndrome in HCC patients after DEB- TACE： a comparative study[J].journal interventional radiology,2020,29(03):722.
[8]肖书萍,肖 芳,郑传胜,等.全周期分阶段护理在载药微球治疗肝癌患者中的应用 [J].介入放射学杂志,2020,29(12):1262.
　XIAO Shuping,XIAO Fang,ZHENG Chuansheng,et al.Application of full-cycle phased nursing care in patients with liver cancer receiving drug-loaded microspheres TACE[J].journal interventional radiology,2020,29(03):1262.
[9]翟越,赵 卫,潘文秋,等.TACE联合载药微球治疗肝癌的研究进展[J].介入放射学杂志,2019,28(12):1211.
　ZHAI Yue,ZHAO Wei,PAN Wenqiu,et al.TACE combined with drug- eluting beads for the treatment of hepatocellular carcinoma： recent progress in research[J].journal interventional radiology,2019,28(03):1211.
[10]王文辉,李宝华,李 雷,等.载药微球治疗中期原发性肝癌25例[J].介入放射学杂志,2021,30(03):270.
　WANG Wenhui,LI Baohua,LI Lei,et al.CalliSpheres-loaded microspheres for the treatment of mid-stage hepatocellular carcinoma： analysis of its efficacy and safety in 25 patients[J].journal interventional radiology,2021,30(03):270.

备注/Memo

备注/Memo:
（收稿日期：2021- 03- 02）
（本文编辑：俞瑞纲）
更新日期/Last Update: 2022-03-17